Akari Therapeutics (AKTX) Company Report

Akari Therapeutics released a CEO Corner segment detailing its 2025 progress and key scientific and operational milestones.
The company is positioned for a potential transition to a clinical-stage oncology company in 2026.
Akari is advancing its novel PH1 spliceosome-modulating payload for antibody-drug conjugates (ADCs), which has demonstrated a dual mechanism of action and compelling preclinical efficacy.
In 2025, Akari announced a strategic manufacturing partnership with WuXi Biologics and initiated IND-enabling studies for AKTX-101, with plans to start its First-in-Human clinical trial by late 2026/early 2027.

Jan 9, 2026, 2:00 PM

Akari Therapeutics Details 2025 Progress and 2026 Clinical Milestones

AKTX

New Projects/Investments

Akari Therapeutics (AKTX) reported significant progress in 2025, advancing its proprietary PH1 payload and lead program, AKTX-101, an antibody drug conjugate (ADC) designed to overcome limitations of existing cancer therapies.
A key milestone in 2025 was the initiation of GMP manufacturing for AKTX-101 with WuXi XDC, signaling the company's transition from preclinical discovery to a clinical-focused biotechnology player.
The company anticipates a transformational 2026, with plans to advance AKTX-101 towards first-in-human trials in late 2026 or early 2027, subject to regulatory clearance.
Upcoming catalysts for 2026 include regulatory interactions with the FDA, completion of CMC and non-clinical work for IND/CTA submissions, and the initiation of the Phase 1 clinical trial.
Akari also strengthened its intellectual property with three new patent filings for its PH1 payload in the last two quarters of 2025.

Dec 30, 2025, 2:15 PM

Akari Therapeutics Announces $5 Million Financing and $4 Million Debt Reduction

AKTX

New Projects/Investments

Akari Therapeutics, Plc announced a $5 million financing through a registered direct offering and a concurrent private placement, with the offering expected to close around December 17, 2025.
This financing included over $1 million in new cash investment from the company's Directors, Officers, and Executive Management.
Concurrently, the company achieved an approximate $4 million non-cash reduction of outstanding note principal by converting existing debt into equity and warrants, resulting in a total combined cash proceeds and liability reduction of approximately $9 million. The net proceeds from the offering will be used for continued research and development, working capital, and general corporate purposes.

Dec 17, 2025, 3:15 PM

Akari Therapeutics Announces $5 Million Financing and Debt Conversion

AKTX

Debt Issuance

New Projects/Investments

Convertible Preferred Issuance

Akari Therapeutics has entered into definitive agreements to issue and sell 12,607,487 American Depositary Shares (ADSs) or ADS equivalents and unregistered warrants through a registered direct offering and a concurrent private placement.
The offering is expected to generate approximately $5 million in gross proceeds, including over $1 million from new cash investments by Directors, Officers, and Executive Management.
Additionally, the company will convert approximately $2.50 million of outstanding debt into unregistered pre-funded warrants and warrants.
The net proceeds are intended for continued research and development, working capital, and general corporate purposes.

Dec 16, 2025, 2:29 PM

Akari Therapeutics Announces $2.5 Million Registered Direct Offering and Private Placement

AKTX

Akari Therapeutics, Plc entered into a securities purchase agreement on October 14, 2025, for a registered direct offering and concurrent private placement.
The company expects to raise approximately $2.5 million in gross proceeds by selling 3,125,000 American Depositary Shares (ADSs) and accompanying Series E and Series F warrants.
The combined purchase price for each ADS and accompanying warrants is $0.80.
Ladenburg Thalmann & Co. Inc. will serve as the exclusive placement agent, earning a 7.2% cash fee, a 0.5% management fee, and warrants to purchase 4.0% of the aggregate number of shares sold.
The net proceeds from the offering are intended for working capital, general corporate purposes, and continued research and development, specifically to generate data on a novel ADC payload.

Oct 16, 2025, 1:20 PM

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

AKTX

Akari Therapeutics, Plc announced a $2.5 million registered direct offering of its American Depositary Shares (ADSs).
The company will issue 3,125,000 ADSs at a purchase price of $0.80 per ADS.
In a concurrent private placement, unregistered Series E and Series F Warrants will be issued, each to purchase up to 3,125,000 ADSs at an exercise price of $0.98 per share.
The gross proceeds, expected to be approximately $2.5 million, will be used for working capital, general corporate purposes, and continued research and development.
The offering is anticipated to close on or about October 16, 2025.

Oct 15, 2025, 12:45 PM

Akari Therapeutics Amends Debt and Warrants, Closes Debt Tranche, and Reports Preclinical Data

AKTX

Debt Issuance

New Projects/Investments

Convertible Preferred Issuance

On September 19, 2025, Akari Therapeutics Plc amended its April 2023 Notes and Warrants, extending the notes' maturity to August 31, 2026, and the warrants' expiration to August 31, 2030. The conversion and exercise prices for both were adjusted to $0.81 per ADS.
The company completed the second tranche of its August 2025 Notes Offering on September 24, 2025, issuing $625,000 in aggregate principal amount of notes for a purchase price of $500,000, bringing the total principal issued to $3.5 million.
Akari Therapeutics Plc also announced on September 24, 2025, positive preclinical data for its novel antibody drug conjugate (ADC) payload, PH1, showing its potential to treat prostate cancer by suppressing AR-V7 expression.

Sep 25, 2025, 9:00 PM

Akari Therapeutics Plc enters into $25 million equity financing agreement

AKTX

Akari Therapeutics Plc entered into an Ordinary Share Purchase Agreement with White Lion Capital, LLC on August 29, 2025, allowing the company to sell up to $25,000,000 in newly issued Ordinary Shares.
The agreement provides Akari Therapeutics Plc with the right, but not the obligation, to sell shares over a Commitment Period ending on the earlier of the full amount being purchased or August 29, 2028.
Sales under the agreement are contingent upon a registration statement covering the resale of the shares being declared effective by the SEC.
As consideration for the agreement, Akari Therapeutics Plc will pay a document preparation fee of $15,000 and additional cash commitment fees based on aggregate purchase notices.